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Chimeric antibodies composed of mouse-derived variable regions and human-derived constant regions have been devel- 
oped for clinical use. However, construction of chimeric mouse/human genes in expression vectors is time-consuming 
work. In this study, we developed convenient vectors for construction of chimeric mouse/human antibodies. The proto- 
cols are as follows: In mouse hybridomas and B cells, most active Vn and V, genes can be identified as rearranged bands 
by Southern hybridization of EcoRI- and HindHI-digested DNAs with Jn and J, probes, respectively, and such fragments 
can be isolated in I-EcoRI and I-Hind111 vectors, respectively. We constructed two plasmids: pSV2-HGlgpt contains 
human C;., and Ecogpt genes, and only one EcoRI site upstream of the C,, gene; pSV2-HC,neo contains human C, and 
neo genes, and only one Hind111 site upstream of the C, gene. An isolated EcoRI fragment containing a VuDnJu gene 
and a Hind111 fragment containing a V,J, gene are inserted into pSV2-HGlgpt and pSV2-HC,neo, respectively. Both 
resulting plasmid DNAs are co-transfected into SP2/0 cell, a non-Ig-secreting mouse myeloma. Transformants are 
selected by both mycophenolic acid and G418. With this procedure, it takes only 2 months to obtain chimeric antibodies. 
DNA, recombinant; Chimeric antibody; Anti-phosphorylchohne 
1. INTRODUCTION 
Since hybridoma technology became available 
[l], many tumor-specific antibodies (Ab) have 
been developed for the diagnosis and treatment of 
cancer [2]. However, since many of these Ab are 
derived from mouse, they have clinical limitations. 
Ab consist of two structurally and functionally dif- 
ferent portions. Variable (V) regions bind antigens 
(Ag) and constant (C) parts bear effector functions 
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such as binding and activation of complements, 
stimulation of phagocytosis by macrophages, and 
triggering of granule release by mast cells. Utilizing 
the dual characters in the structure of Ab, two 
research groups [3,4] succeeded in constructing 
chimeric molecules consisting of mouse-derived V 
regions and human-derived C regions. These 
chimeric Ab retained specificity for the haptens 
phosphorylcholine (PC) [3] and trinitrophenyl [4]. 
Since these studies several groups have reported 
production of similar chimeric Ab showing an- 
titumor activities [5-l 11. 
Since three fragments, a mouse-derived active V 
gene-containing fragment, a human-derived C 
gene-containing fragment and an expression vec- 
tor, must be properly connected to construct 
chimeric genes of heavy (H) and light (L) chains, 
this work is time-consuming. In fact, various 
restriction sites have been utilized in the published 
cases [3-l 11. One of the authors (Y.K.) isolated 
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fifteen different active Vn genes in Dr Tonegawa’s 
laboratory (MIT) [12,13], and noticed that the 
sizes of active VH gene-containing EcoRI 
fragments ranged from 2 to 20 kb in most 
myeloma cells [14]. Here, we constructed conve- 
nient vectors for construction of chimeric 
mouse/human Ab. Our protocols avoid a time- 
consuming step in obtaining chimeric Ab. 
2. MATERIALS AND METHODS 
2.1. Vectors, clones, probes, linkers and cells 
AWES [15] and h7ss [16] were used as EcoRI and Hind111 phage 
vectors, respectively. pSV2gpt [17] and pSV2neo [18] were pro- 
vided by P. Berg (Stanford). Mouse J, gene-containing frag- 
ment (JX probe) was isolated from clone Ig146 [19]. Mouse JH 
probe was isolated from MEP203 [20]. Mouse C,r-containing 
clone MEPlO was donated by S. Tonegawa (MIT) [21]. Human 
HaeIII-A[uI genomic library was donated by T. Maniatis (Har- 
vard) [22]. Three oligonucleotides: GGAATTCC, CAAGC- 
TTG and CGGATCCG were used as EcoRI, Hind111 and 
BamHI linkers, respectively. A myeloma TEPClS was obtained 
from M. Potter (NIH). SP2/0 was obtained from ATCC. 
2.2. Cloning of human C, and C,.I genes 
Clone HuC,2 containing human J, genes, enhancer egion 
and C, gene was obtained by screening the human genomic 
library [22] with mouse J, probe. Clone HG163 containing 
human C$ gene was isolated as follows: human placenta DNA 
was digested with Hind111 and fractionated by agarose gel elec- 
trophoresis. A library was constructed from 8.4-8.8 kb long 
DNA in h,ss vector. Clone HG163 was obtained by screening 
with mouse C,r probe. Since the sizes of four different C, gene- 
containing fragments are similar to each other [23], we partially 
sequenced HG163 to ascertain C$r gene in the clone [24]. 
2.3. Cloning of size-fractionated DNA 
Active V gene-containing fragments were identified as rear- 
ranged bands in Southern hybridization of NindIII- and EcoRI- 
digested DNAs with J, and JH probes, respectively. DNAs were 
eluted from the relevant regions separated on agarose gel, 
ligated with A7ss and &ES arms, and packaged into h phage. 
Plaque hybridization was carried out according to Benton and 
Davis [25]. 
2.4. Introduction of DNA into myeloma cells by 
electroporation 
SP2/0 cells, a non-Ig-secreting mouse myeloma, were used as 
host for transfection [26]. Electroporation was carried out 
essentially as in [27]. In brief, approx. 2 x 10’ cells were sub- 
jected to an electric field of 1.5 kV/cm twice in 0.5 ml 
phosphate-buffered saline (PBS) containing 50,ag DNAs of 
pSV2HGlVpc and pSV2HCxVpc on ice. Conditions were set to 
cause 50% cell death after electroporation. After incubation on 
ice for 5 min, the cells were transferred to RPM1 1640 medium 
supplemented with 10% fetal calf serum. After incubation at 
37OC for 72 h, the cells were transferred into selection medium 
302 
(RPM1 1640 medium containing 10% fetal calf serum, 5 pg/ml 
mycophenolic acid and 250 yg/ml xanthine). Transformants 
were further analyzed for resistance to G418 (4OOpg/ml). The 
cells showing resistance to both mycophenolic acid and G418 
were grown. 
2.5. Enzyme-linked immunosorbent assay (ELBA) 
Production of chimeric Ab by the transformed cells was 
assayed by ELISA. Microtiter plates (96 wells) were coated with 
100 ,ul anti-human immunoglobulin (Ig) per well by incubation 
at room temperature for 1 h, and plates were washed three 
times with PBS containing 0.5% BSA (buffer). 50~1 of each 
supernatant were added to each well, and incubation carried out 
at 40°C for 1 h. Plates were washed three times with buffer, 
and 100~1 peroxidase-conjugated goat anti-human IgG (Fc 
fragment) Ab or goat anti-human x-chain Ab was added and in- 
cubated at 40°C for 1 h. Plates were washed four times with 
buffer and 100~1 of a mixture containing 0.04% o- 
phenylenediamine, 0.033% HsOs, 25 mM citric acid, and 
50 mM NazHPOd (pH 5.0) were added to each well. The reac- 
tion was stopped with 2.5 M HzS04, and the absorbance (A) at 
492 nm was measured. Purified human IgG was used as a con- 
trol. SPZ-PC Chimera-l cells were injected into Balb/c mouse 
bellies, the mice having received 500 &mouse of pristane 
(2,6,10,14-tetramethylpentadecane; Wako, Osaka) 2 weeks 
previously. Ascites were used in the following experiments. 
2.6. Western blotting 
Protein samples were suspended in 32 mM Tris-HCI, pH 6.8, 
1% SDS, 5% glycerol, 0.005% bromophenol blue, and 2.5@/0,& 
mercaptoethanol. After incubation at 100°C for 2 min, the pro- 
teins were separated by SDS-PAGE on an 8-18% linear gra- 
dient containing 0.1% SDS [28], and electrophoretically 
transferred to nitrocellulose membrane as described by Towbin 
et al. [29]. The membrane was blocked with 3% gelatin in TBS 
(150 mM NaCl, 20 mM Tris-HCl, pH 7.5) at room temperature 
for 1 h, and incubated for 3 h with a mixture of rabbit anti- 
human IgG and x-chain Ab diluted 300 times in TBS containing 
1% gelatin. The membrane was washed three times with TBS 
containing 0.05% Tween20 for 10 mitt, and was incubated for 
1 h with peroxidase-conjugated goat anti-rabbit second Ab 
diluted 3000 times in TBS containing 1% gelatin. The mem- 
brane was washed and reacted with 4-chloro-1-naphthol-Hz02 
color-producing solution and rinsed with water. Rabbit anti- 
human IgG Ab, rabbit anti-human x-chain Ab and peroxidase- 
conjugated goat anti-rabbit Ab were purchased from Cappel. 
4-Chloro-1-naphthol was purchased from Wako. 
2.7. Antibody-binding assay 
PC-binding activity of the chimeric Ab was assayed as 
follows: Microtiter plates (96 wells) were coated with 25 ~1 PC- 
OVA (100 rg/ml) per well by overnight incubation at 4”C, 
150~1 of buffer was added and incubation was performed at 
room temperature for 0.5 h. Plates were washed three times 
with buffer and 25 ~1 ascites was added. The plates were then 
incubated at room temperature for 1 h, washed three times with 
buffer, and 40 pl alkaline phosphatase-conjugated anti-human 
Ig Ab was added. Subsequently, they were incubated at room 
temperature for 1 h, washed four times with buffer, and 100 ~1 
of a mixture (pH 9.8) containing 0.1% (w/v) p-nitrophenol 
phosphate, 9.7% diethanolamine, 0.01% (w/v) MgC12*6HzO, 
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and 0.02% (w/v) NaNs was added per well. The reaction was 
stopped with 3 M NaOH and A at 405 nm was measured. 
3. RESULTS AND DISCUSSION 
3.1. Construction of plasmids: pSV2-HGlgpt and 
pS V2-HC,neo 
Fig.1 shows the plasmid construction scheme: 
pSVZHG1gpt and pSV2-HC,neo. The 8.5 kb 
Hind111 fragment containing human C,r gene was 
isolated from clone HG163, treated with Klenow 
enzyme and ligated with an EcoRI linker. The 
fragment was then digested with EcoRI and 
BamHI, and inserted into the EcoRI-BamHI sites 
of pSV2gpt [17], resulting in pSV2-HGlgpt. It 
contains human Gr and Ecogpt genes, and only 
one EcoRI site upstream of the C,r gene. It does 
not contain an enhancer sequence. 
The Hind111 site located at the junction between 
SV40 promoter and neo gene in the original 
pSV2neo plasmid [18] was destroyed as follows: 
pSV2neo DNA was linearized by Hind111 diges- 
tion, and both ends were converted into blunt ends 
with Klenow enzyme, and re-ligated. The resulting 
plasmid kept the phenotype of G418 resistance 
(not shown). The EcoRI site of the plasmid was 
converted into a Hind111 site using a Hind111 
linker. The 2.1 kb PuuII fragment (the 3 ’ portion 
of this fragment was derived from Charon 4A vec- 
tor) containing a human enhancer region and C, 
gene was isolated from clone HuC,2, and ligated 
with a mixture of Hind111 and BamHI linkers. 
After digestion of this fragment with both Hind111 
and BamHI, it was inserted into the HindIII- 
BamHI sites of the above-modified pSV2neo 
plasmid. We selected a clone which contains a Hin- 
dII1 site upstream of the C, gene and a BamHI site 
downstream of the C, gene, and named it 
pSVZHC,neo. 
3.2. Isolation of active V genes 
In germline genome, V regions of Ig are encoded 
by two split genes: V and J (joining) genes for L 
chains, and three split genes: V, D (diversity) and 
J genes for H chains [30]. In mouse, there exist 
200-300 V, and four J, genes; two VA and three J,+ 
genes; about 100 VH, 12 Du and four Ju genes 
(review [31]). More than 95% of Ig are x-type and 
the rest A-type. Since these genes undergo DNA 
rearrangements such as V-(D)-J during B-cell on- 
togeny, active V genes can be identified on rear- 
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Fig.1. Construction of plasmids: pSV2-HGlgpt (a) and 
pSV2-HC,neo (b). Restriction maps of the immunoglobulin Jn, 
C, and C, gene loci as well as J, and C, gene loci in both human 
and mouse are shown. AVHTlS and AV,TlS are active Vu and 
V, genes from myeloma TEPClS. DNA regions involved in 
constructed plasmids are indicated by thick bars. Thick arrows 
indicate the position where active V genes hould be inserted. Ju 
and J, probes are indicated by hatched bars. En, enhancer; Ori, 
pBR322 ori; Amp, fl-lactamase; SV40, SV40 promoter; polyA, 
poly(A) attachment signal. E, EcoRI; P, PvuII; B, BarnHI; H, 
HindUI. 
ranged fragments by Southern hybridization with J 
gene-containing DNAs as probes. EcoRI and Hin- 
dII1 digestions are practical for H- and x-chains, 
respectively, since the sizes of rearranged 
fragments range from 2 to 20 kb in most cases 
[ 141. Maintaining a high level expression of Ig 
genes in B cells requires characteristic octamer se- 
quences located upstream of V genes [32] and 
enhancer elements located in Ju-p and J,-C, in- 
trons [33,34]. Although pSVZHGlgpt does not 
contain the enhancer sequence, a Jn gene- 
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containing EcoRI fragment includes the enhancer 
sequence. On the other hand, a J, gene-containing 
Hind111 fragment does not contain the enhancer 
sequence, but is included in pSVZHC,neo. The 
enhancer sequence of human origin is effective in 
mouse cells. Based on the above principles, we 
isolated active Vu and V, genes from anti-PC 
myeloma, TEPClS. As shown in fig.2, Jn probe 
identified one rearranged band at 7 kb in EcoRI- 
digested TEPC15 DNA. We cloned this band 
(named XVnTlS) as an active Vn gene-containing 
fragment [35]. J, probe identified one rearranged 
band at 5 kb in addition to a germline band at 3 kb 
in HindIII-digested TEPC15 DNA. We cloned the 
5 kb band (named hV,T15). The restriction map of 
this clone is the same as for the published V, clone 
[36]. A general protocol for identification of active 
V gene-containing fragments is described later. 
3.3. Production of anti-PC chimeric Ab 
The 7 kb EcoRI fragment was isolated from 
hVnT15 clone and inserted into the EcoRI site of 
pSVZHGlgpt. We selected a clone in which the 
polarities of the Vn and CH genes are the same, 
and designated it pSV2HGlVpc. The 5 kb Hind111 
fragment was isolated from hV,TlS clone, and in- 
serted into the Hind111 site of pSVZC,neo. A 
proper clone containing V, and C, of the same 
polarity was selected, and named pSV2HCxVpc. 
Both plasmid DNAs were co-transfected into 
SP2/0 cells by electroporation as described in sec- 
tion 2. First, cells were selected in Ecogpt selection 
medium. The frequency of transformants was ap- 
prox. 10U5. One-third of the transformants also 
showed G418 resistance. Transformants resistant 
to both mycophenolic acid and G418 were grown, 
and amounts of Ab secreted into the culture super- 
natants were measured by ELISA. One of the 
stable transformants (SP2-PC Chimera-l) produc- 
ing a high level of Ab (5 pg/ml) was cloned by 
limiting dilution. SP2-PC Chimera-l cells were in- 
jected into Balb/c mouse belly. After growth of 
the tumor, the ascites was analyzed. Fig.3 shows 
the results of Western blotting. Chimeric an- 
tibodies were reacted with a mixture of anti-human 
Ig and x-chain Ab (lane I). They discriminate be- 
tween human and mouse Ab (lanes 2,3). 
Moreover, the chimeric Ab bound to PC-OVA, 
but not PAB-OVA as shown in fig.4. The chimeric 
Ab clearly retained the original antigen specificity. 
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Fig.2. Southern hybridization of TEPClS DNA. (a) Balb/c 
mouse kidney DNA (lane 1) and TEPClS DNA (lane 2) were 
digested with EcoRI. Probe was JH probe. (b) Balb/c mouse 
kidney DNA (lane 1) and TEPClS DNA (lane 2) were digested 
with HindHI. Probe was J, probe. 
3.4. Standard protocols for chimeric Ab 
production 
In the case of hybridomas, we adopted the 
following criteria for identification of active V 
gene-containing fragments. First, active V genes 
should be on rearranged fragments which are iden- 
tified only in hybridoma DNA, not in the fusion 
partner’s DNA. If there are two candidate bands, 
we clone both of them. In the case of H chains, 
since many abortive rearranged bands contain the 
Dn-Jn structure without Vn genes [141, they can be 
differentiated from active V gene-containing 
fragments by Southern hybridization with Dn 
probes. Although 12 Dn genes have been identified 
in mouse, 11 of them can be identified with one DH 
probe, the DSPZ probe, and the remaining one with 
the Do52 probe [37]. Active VHDHJH gene does not 
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Fig.3. Western blotting of chimeric, human and mouse Ab. (a) 
2 ,ul of 10 times diluted ascites from SPZ-PC chimera-l cell- 
injected mouse (lane l), 5 81 of 1000 times diluted normal 
human serum (lane 2) and 1 pl of 10 times diluted normal 
mouse serum (lane 3) were applied to SDS-PAGE. (b) 5rl of 
100 times diluted ascites (lane 1) and 1 ~1 of 1000 times diluted 
normal human serum (lane 2) were applied without 
mercaptoethanol treatment. 
give a positive signal to the Dn probes, since a Dn- 
coding region is too short to be hybridized with the 
DH probes. Second, active V genes should be ex- 
pressed in the hybridomas. This can be examined 
by Northern hybridization of mRNA from the 
hybridoma with the isolated fragments as probes. 
In most cases, these two criteria are sufficient for 
identification of active V gene-containing 
fragments. The isolated EcoRI fragment contain- 
ing a VHDHJH gene and the Hind111 fragment con- 
taining a V,J, gene are treated in the same way as 
TEPClS DNA described in this paper. We made 
chimeric antibodies according to these protocols 
by using monoclonal antibody M2590, which 
shows preferential reactivity with various types of 
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Fig.4. Specific PC-binding activity of chimeric antibody. Anti- 
PC chimeric antibody (M) in ascites in various dilutions 
reacted with PC-OVA (a) or PAB @-azobenzenarsonate)-OVA 
(b) coated plates as described in section 2. Mouse/human 
chimeric antibody constructed with anti-GM3 mouse IgV and 
human Igh.C$ under the same conditions as described here 
was used as a control chimeric antibody (o--o). 
elsewhere). If the Ig is h-type, we cannot use these 
protocols. Also, if an EcoRI site exists in the pro- 
moter and coding regions of a Vn gene, or if a Hin- 
dII1 site exists in those of a V, gene, we need other 
devices. Using these protocols, it takes 2 months to 
obtain chimeric Ab. 
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